Dual diagnosis (also called co-occurring disorders, COD, or dual pathology) is the condition of suffering from a mental illness and a comorbid substance use disorder. There is considerable debate surrounding the appropriateness of using a single category for a heterogeneous group of individuals with complex needs and a varied range of problems. The concept can be used broadly, for example depression and alcohol use disorder, or it can be restricted to specify severe mental illness (e.g. psychosis, schizophrenia) and substance use disorder (e.g. cannabis use), or a person who has a milder mental illness and a drug dependency, such as panic disorder or generalized anxiety disorder and is dependent on opioids. Diagnosing a primary psychiatric illness in people who use substances is challenging as substance use disorder itself often induces psychiatric symptoms, thus making it necessary to differentiate between substance induced and pre-existing mental illness.
Those with co-occurring disorders face complex challenges. They have increased rates of relapse, hospitalization, homelessness, and HIV and hepatitis C infection compared to those with either mental or substance use disorders alone.
Differentiating pre-existing and substance induced
The identification of substance-induced versus independent psychiatric symptoms or disorders has important treatment implications and often constitutes a challenge in daily clinical practice. Similar patterns of comorbidity and risk factors in individuals with substance induced disorder and those with independent non-substance induced psychiatric symptoms suggest that the two conditions may share underlying etiologic factors.
Substance use disorders, including those of alcohol and prescription medications, can induce a set of symptoms which resembles mental illness, which can make it difficult to differentiate between substance induced psychiatric syndromes and pre-existing mental health problems. More often than not psychiatric disorders among people who use alcohol or illicit substances disappear with prolonged abstinence. Substance induced psychiatric symptoms can occur both in the intoxicated state and also during the withdrawal state. In some cases these substance induced psychiatric disorders can persist long after detoxification, such as prolonged psychosis or depression after amphetamine or cocaine use. Use of hallucinogens can trigger delusional and other psychotic phenomena long after cessation of use and cannabis may trigger panic attacks during intoxication and with use it may cause a state similar to dysthymia. Severe anxiety and depression are commonly induced by sustained alcohol use which in most cases abates with prolonged abstinence. Even moderate sustained use of alcohol may increase anxiety and depression levels in some individuals. In most cases these drug induced psychiatric disorders fade away with prolonged abstinence. A protracted withdrawal syndrome can also occur with psychiatric and other symptoms persisting for months after cessation of use. Among the currently prevalent medications, benzodiazepines are the most notable drug for inducing prolonged withdrawal effects with symptoms sometimes persisting for years after cessation of use.
Prospective epidemiological studies do not support the hypotheses that comorbidity of substance use disorders with other psychiatric illnesses is primarily a consequence of substance use or dependence or that increasing comorbidity is largely attributable to increasing use of substances. Yet emphasis is often on the effects of substances on the brain creating the impression that dual disorders are a natural consequence of these substances. However addictive drugs or exposure to gambling will not lead to addictive behaviors or drug dependence in most individuals but only in vulnerable ones, although, according to some researchers, neuroadaptation or regulation of neuronal plasticity, and molecular changes, may alter gene expression in some cases and subsequently lead to substance use disorders.
Research instruments are also often insufficiently sensitive to discriminate between independent, true dual pathology, and substance-induced symptoms. Structured instruments, as Global Appraisal of Individual Needs - Short Screener-GAIN-SS and Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV-PRISM, have been developed to increase the diagnostic validity. While structured instruments can help organize diagnostic information, clinicians must still make judgments on the origin of symptoms.
Comorbidity of addictive disorders and other psychiatric disorders, i.e., dual disorders, is very common and a large body of literature has accumulated demonstrating that mental disorders are strongly associated with substance use disorders. The 2011 USA National Survey on Drug Use and Health found that 17.5% of adults with a mental illness had a co-occurring substance use disorder; this works out to 7.98 million people. Estimates of co-occurring disorders in Canada are even higher, with an estimated 40-60% of adults with a severe and persistent mental illness experiencing a substance use disorder in their lifetime.
A study by Kessler et al. in the United States attempting to assess the prevalence of dual diagnosis found that 47% of clients with schizophrenia had a substance misuse disorder at some time in their life, and the chances of developing a substance misuse disorder was significantly higher among patients suffering from a psychotic illness than in those without a psychotic illness.
Another study looked at the extent of substance misuse in a group of 187 chronically mentally ill patients living in the community. According to the clinician's ratings, around a third of the sample used alcohol, street drugs, or both during the six months before evaluation.
Further UK studies have shown slightly more moderate rates of substance misuse among mentally ill individuals. One study found that individuals suffering from schizophrenia showed just a 7% prevalence of problematic drug use in the year prior to being interviewed and 21% reported problematic use some time before that.
Wright and colleagues identified individuals with psychotic illnesses who had been in contact with services in the London borough of Croydon over the previous 6 months. Cases of alcohol or substance misuse and dependence were identified through standardized interviews with clients and keyworkers. Results showed that prevalence rates of dual diagnosis were 33% for the use of any substance, 20% for alcohol misuse only and 5% for drug misuse only.[clarification needed] A lifetime history of any illicit drug use was observed in 35% of the sample.
Substance use disorders can be confused with other psychiatric disorders. There are diagnoses for substance-induced mood disorders and substance-induced anxiety disorders and thus such overlap can be complicated. For this reason, the DSM-IV advises that diagnoses of primary psychiatric disorders not be made in the absence of sobriety (of duration sufficient to allow for any substance-induced post-acute-withdrawal symptoms to dissipate) up to 1 year.
Only a small proportion of those with co-occurring disorders actually receive treatment for both disorders. Therefore, it was argued that a new approach is needed to enable clinicians, researchers and managers to offer adequate assessment and evidence-based treatments to patients with dual pathology, who cannot be adequately and efficiently managed by cross-referral between psychiatric and addiction services as currently configured and resourced. In 2011, it was estimated that only 12.4% of American adults with co-occurring disorders were receiving both mental health and addictions treatment. Clients with co-occurring disorders face challenges accessing treatment, as they may be excluded from mental health services if they admit to a substance use problem, and vice versa.
There are multiple approaches to treat concurrent disorders. Partial treatment involves treating only the disorder that is considered primary. Sequential treatment involves treating the primary disorder first, and then treating the secondary disorder after the primary disorder has been stabilized. Parallel treatment involves the client receiving mental health services from one provider, and addictions services from another.
Integrated treatment involves a seamless blending of interventions into a single coherent treatment package developed with a consistent philosophy and approach among care providers. With this approach, both disorders are considered primary. Integrated treatment can improve accessibility, service individualization, engagement in treatment, treatment compliance, mental health symptoms, and overall outcomes. The Substance Abuse and Mental Health Services Administration in the United States describes integrated treatment as being in the best interests or clients, programs, funders, and systems. Green suggested that treatment should be integrated, and a collaborative process between the treatment team and the patient. Furthermore, recovery should to be viewed as a marathon rather than a sprint, and methods and outcome goals should be explicit.
A 2019 Cochrane meta-analysis that included 41 randomized controlled trials found no high-quality evidence in support of any one psycho-social intervention over standard care for outcomes such as remaining in treatment, reduction in substance use and/or improvement in global functioning and mental status.
Theories of dual diagnosis
There are a number of theories that explain the relationship between mental illness and substance use.
The causality theory suggests that certain types of substance use may causally lead to mental illness.
There is strong evidence that using cannabis can produce psychotic and affective experiences. When it comes to persisting effects, there is a clear increase in incidence of psychotic outcomes in people who had used cannabis, even when they had used it only once. More frequent use of cannabis strongly augmented the risk for psychosis. The evidence for affective outcomes is less strong. However, this connection between cannabis and psychosis does not prove that cannabis causes psychotic disorders. The causality theory for cannabis has been challenged as despite explosive increases in cannabis consumption over the past 40 years in western society, the rate of schizophrenia (and psychosis in general) has remained relatively stable.
Attention-deficit hyperactivity disorder
One in four people who have a substance use disorder also have attention-deficit hyperactivity disorder, which makes the treatment of both conditions more difficult. ADHD is associated with an increased craving for drugs. Having ADHD makes it more likely that an individual will initiate substance misuse at a younger age than their peers. They are also more likely to experience poorer outcomes, such as longer time to remission, and to have increased psychiatric complications from substance misuse. While generally stimulant medications do not seem to worsen substance use, they are known to be non-medically used in some cases. Psychosocial therapy and/or nonstimulant medications and extended release stimulants are ADHD treatment options that reduce these risks.
Autism spectrum disorder
Unlike ADHD, which significantly increases the risk of substance use disorder, autism spectrum disorder has the opposite effect of significantly reducing the risk of substance use. This is because introversion, inhibition and lack of sensation seeking personality traits, which are typical of autism spectrum disorder, protect against substance use and thus substance use levels are low in individuals who are on the autism spectrum. However, certain forms of substance use disorders, especially alcohol use disorder, can cause or worsen certain neuropsychological symptoms which are common to autism spectrum disorder. This includes impaired social skills due to the neurotoxic effects of alcohol on the brain, especially in the prefrontal cortex area of the brain. The social skills that are impaired by alcohol use disorder include impairments in perceiving facial emotions, prosody perception problems and theory of mind deficits; the ability to understand humour is also impaired in people who consume excessive amounts of alcohol
The inclusion of behavioral addictions like pathological gambling must change our way of understanding and dealing with addictions. Pathological (disordered) gambling has commonalities in clinical expression, etiology, comorbidity, physiology and treatment with substance use disorders (DSM-5). A challenge is to understand the development of compulsivity at a neurochemical level not only for drugs.
Past exposure to psychiatric medications theory
The past exposure theory suggests that exposure to psychiatric medication alters neural synapses, introducing an imbalance that was not previously present. Discontinuation of the drug is expected to result in symptoms of psychiatric illness which resolve once the drug is restarted. This theory suggests that while it may appear that the medication is working, it is only treating a disorder caused by the medication itself. New exposure to psychiatric medication may lead to heightened sensitivity to the effects of drugs such as alcohol, which has a deteriorating effect on the patient.
The self-medication theory suggests that people with severe mental illnesses misuse substances in order to relieve a specific set of symptoms and counter the negative side-effects of antipsychotic medication.
Khantizan proposes that substances are not randomly chosen, but are specifically selected for their effects. For example, using stimulants such as nicotine or amphetamines can be used to combat the sedation that can be caused by higher doses of certain types of antipsychotic medication. Conversely, some people taking medications with a stimulant effect such as the SNRI antidepressants Effexor (venlafaxine) or Wellbutrin (bupropion) may seek out benzodiazepines or opioid narcotics to counter the anxiety and insomnia that such medications sometimes evoke.
Some studies show that nicotine administration can be effective for reducing motor side-effects of antipsychotics, with both bradykinesia (stiff muscles) and dyskinesia (involuntary movement) being prevented.
Alleviation of dysphoria theory
The alleviation of dysphoria theory suggests that people with severe mental illness commonly have a negative self-image, which makes them vulnerable to using psychoactive substances to alleviate these feelings. Despite the existence of a wide range of dysphoric feelings (anxiety, depression, boredom, and loneliness), the literature on self-reported reasons for use seems to lend support for the experience of these feelings being the primary motivator for alcohol use disorder and other drug misuse.
Multiple risk factor theory
Another theory is that there may be shared risk factors that can lead to both substance use and mental illness. Mueser hypothesizes that these may include factors such as social isolation, poverty, lack of structured daily activity, lack of adult role responsibility, living in areas with high drug availability, and association with people who already misuse drugs.
The supersensitivity theory
The supersensitivity theory proposes that certain individuals who have severe mental illness also have biological and psychological vulnerabilities, caused by genetic and early environmental life events. These interact with stressful life events and can result in either a psychiatric disorder or trigger a relapse into an existing illness. The theory states that although anti-psychotic medication can reduce the vulnerability, substance use may increase it, causing the individual to be more likely to experience negative consequences from using relatively small amounts of substances. These individuals, therefore, are "supersensitive" to the effects of certain substances, and individuals with psychotic illness such as schizophrenia may be less capable of sustaining moderate substance use over time without experiencing negative symptoms.
Although there are limitations in the research studies conducted in this area, namely that most have focused primarily on schizophrenia, this theory provides an explanation of why relatively low levels of substance misuse often result in negative consequences for individuals with severe mental illness.
Avoiding categorical diagnosis
Current nosological approach does not provide a framework for internal (sub-threshold symptoms) or external (comorbidity) heterogeneity of the different diagnostic categories. The prevailing "Neo-Kraepelinian" diagnostic system solely accounts for a categorical diagnosis, therefore not allowing for the possibility of dual diagnosis. There has been substantial criticism to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), due to problems of diagnostic overlap, lack of clear boundaries between normality and disease, a failure to take into account findings from novel research and the lack of diagnostic stability over time.
The traditional method for treating patients suffering from dual diagnosis was a parallel treatment program. In this format, patients received mental health services from one clinician while addressing their substance use with a separate clinician. However, researchers found that parallel treatments were ineffective, suggesting a need to integrate the services addressing mental health with those addressing substance use.
During the mid-1980s, a number of initiatives began to combine mental health and substance use disorder services in an attempt to meet this need. These programs worked to shift the method of treatment for substance use from a confrontational approach to a supportive one. They also introduced new methods to motivate clients and worked with them to develop long-term goals for their care. Although the studies conducted by these initiatives did not have control groups, their results were promising and became the basis for more rigorous efforts to study and develop models of integrated treatment.
- "Report to Congress on the prevention and treatment of co-occurring substance abuse disorders disorders". SAMHSA. November 2001. Archived from the original on 1 May 2012. Retrieved 1 May 2012.
- Casas M. Trastornos duales. Vallejo Ruiloba J, Gastó Ferrer C (eds). Trastornos afectivos: ansiedad y depresión (2ª ed). Barcelona, Masson; 2000:890-899.
- Charles, Atkins (2014). Co-Occurring Disorders: Integrated Assessment and Treatment of Substance Use and Mental Disorders. [Place of publication not identified]: Pesi Publishing & Media. ISBN 978-1937661526. OCLC 899586899.
- Austin, Infinite Recovery; USA –206-9063, Austin Drug Rehab. "Sober Living Austin". Infinite Recovery. Retrieved 19 February 2019.
- Standing Senate Committee on Social Affairs, Science, and Technology (2006). "Out of the Shadows at Last: Transforming Mental Health, Mental Illness and Addictions Services in Canada" (PDF). Government of Canada. Retrieved 2 February 2019.CS1 maint: multiple names: authors list (link)
- Blanco 2012 p. 865-873.
- Evans, Katie; Sullivan, Michael J. (1 March 2001). Dual Diagnosis: Counseling the Mentally Ill Substance Abuser (2nd ed.). Guilford Press. pp. 75–76. ISBN 978-1-57230-446-8.
- Frisher 2005 p. 847-850.
- Hasin 2006 p. 689-696
- Adamson 2006 p. 164-170; Hasin et al, 2011
- "What Are Co-Occurring Disorders?". Oxford Treatment Center. Retrieved 18 January 2021.
- Substance Abuse and Mental Health Services Administration (2012). "Results from the 2011 National Survey on Drug Use and Health: Mental Health Findings". Retrieved 5 April 2013.
- Health Canada (2012). "Best Practices: Concurrent Mental Health and Substance Use Disorders" (PDF). Government of Canada. Retrieved 5 April 2013.
- Kessler RC; McGonagle KA; Zhao S; Nelson CB; Hughes M; Eshleman S; Wittchen HU; Kendler KS (1994). "Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey" (PDF). Archives of General Psychiatry. 51 (1): 8–19. doi:10.1001/archpsyc.1994.03950010008002. PMID 8279933.
- Regier DA; Farmer ME; Rae DS; Locke BZ; Keith SJ; Judd LL; Goodwin FK (1990). "Comorbidity of mental disorders with alcohol and other drug use. Results from the Epidemiologic Catchment Area (ECA) Study". JAMA. 264 (19): 2511–18. doi:10.1001/jama.264.19.2511. PMID 2232018.
- Drake RE; Wallach MA (1993). "Moderate drinking among people with severe mental illness". Hospital & Community Psychiatry. 44 (8): 780–2. doi:10.1176/ps.44.8.780. PMID 8375841.
- Cantwell, R; Scottish Comorbidity Study Group (2003). "Substance use and schizophrenia: effects on symptoms, social functioning and service use". British Journal of Psychiatry. 182 (4): 324–9. doi:10.1192/bjp.182.4.324. PMID 12668408.
- Wright S; Gournay K; Glorney E; Thornicroft G (2000). "Dual diagnosis in the suburbs: prevalence, need, and in-patient service use". Social Psychiatry & Psychiatric Epidemiology. 35 (7): 297–304. doi:10.1007/s001270050242. PMID 11016524. S2CID 9925528.
- Weaver T, Madden P, Charles V, et al. (2003). "Comorbidity of substance misuse and mental illness in community mental health and substance misuse services". Br J Psychiatry. 183 (4): 304–313. doi:10.1192/bjp.183.4.304. PMID 14519608.
- Drake RE Mueser KT Brunette MR McHugo GJ (2004). "A Review of Treatments for People with Severe Mental Illness and Co-Occurring Substance Use Disorders". Psychiatric Rehabilitation Journal. 27 (4): 360–374. doi:10.2975/27.2004.360.374. PMID 15222148.
- Sciacca, Kathleen_2009. "Best Practices for Dual Diagnosis Treatment and Program Development: Co-occurring Mental Illness and Substance Disorders in Various Combinations". In Angela Brown-Miller (ed.). The Praeger International Collection on Addictions. 3. Praeger. pp. 161–188.
- Center for Co-Occurring Disorders (2006). "Overarching Principles to Address the Needs of Persons with Co-Occurring Disorders" (PDF). Substance and Mental Health Services Administration. Archived from the original (PDF) on 6 October 2014. Retrieved 5 April 2013.
- American Psychiatric Association (2006). "Practice Guidelines for the Treatment of Patients with Substance Use Disorders, 2nd ed". Archived from the original on 14 February 2013. Retrieved 5 April 2013.
- Rush B Fobb B Nadeau L Furlong A (2008). "On the Intregation of Mental Health and Substance Use Services and Systems: Main Report" (PDF). Canadian Executive Council on Addictions. Archived from the original (PDF) on 3 December 2011. Retrieved 5 April 2013.
- Green MD (19 March 2009). "Development of a Dual Disorders Program Methodology for Better Outcomes". Psychiatric Times.
- Hunt, Glenn E.; Siegfried, Nandi; Morley, Kirsten; Brooke-Sumner, Carrie; Cleary, Michelle (12 December 2019). "Psychosocial interventions for people with both severe mental illness and substance misuse". The Cochrane Database of Systematic Reviews. 12: CD001088. doi:10.1002/14651858.CD001088.pub4. ISSN 1469-493X. PMC 6906736. PMID 31829430.
- Mueser KT; Essock SM; Drake RE; Wolfe RS; Frisman L (2001). "Rural and urban differences in patients with a dual diagnosis". Schizophrenia Research. 48 (1): 93–107. doi:10.1016/S0920-9964(00)00065-7. PMID 11278157. S2CID 21853465.
- Moore TH; Zammit S; Lingford-Hughes A; Barnes TR; Jones PB; Burke M; Lewis G (2007). "Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review" (PDF). The Lancet. 370 (9584): 319–28. doi:10.1016/S0140-6736(07)61162-3. PMID 17662880. S2CID 41595474. Archived from the original (PDF) on 16 October 2012. Retrieved 10 April 2013.
- Degenhardt L, Hall W, Lynskey M (2001). "Comorbidity between cannabis use and psychosis: Modelling some possible relationships" (PDF). Technical Report No. 121. Sydney: National Drug and Alcohol Research Centre. Archived from the original (PDF) on 19 August 2006. Retrieved 19 August 2006. Cite journal requires
- Martin Frisher; Ilana Crome; Orsolina Martino; Peter Croft. (2009). "Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005" (PDF). Schizophrenia Research. 113 (2–3): 123–128. doi:10.1016/j.schres.2009.05.031. PMID 19560900. S2CID 1232989.
- "Archived copy" (PDF). Archived from the original (PDF) on 22 September 2010. Retrieved 5 July 2010.CS1 maint: archived copy as title (link) Key facts and trends in mental health, National Health Service, 2009
- van Emmerik-van Oortmerssen, K.; van de Glind, G.; van den Brink, W.; Smit, F.; Crunelle, CL.; Swets, M.; Schoevers, RA. (April 2012). "Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis". Drug Alcohol Depend. 122 (1–2): 11–9. doi:10.1016/j.drugalcdep.2011.12.007. PMID 22209385.
- Frodl, T. (September 2010). "Comorbidity of ADHD and Substance Use Disorder (SUD): a neuroimaging perspective". J Atten Disord. 14 (2): 109–20. doi:10.1177/1087054710365054. PMID 20495160. S2CID 24808462.
- Upadhyaya, HP. (2007). "Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder". J Clin Psychiatry. 68 Suppl 11: 23–30. PMID 18307378.
- Ramos, M.; Boada, L.; Moreno, C.; Llorente, C.; Romo, J.; Parellada, M. (August 2013). "Attitude and risk of substance use in adolescents diagnosed with Asperger syndrome". Drug Alcohol Depend. 133 (2): 535–40. doi:10.1016/j.drugalcdep.2013.07.022. PMID 23962420.
- Uekermann J, Daum I (May 2008). "Social cognition in alcoholism: a link to prefrontal cortex dysfunction?". Addiction. 103 (5): 726–35. doi:10.1111/j.1360-0443.2008.02157.x. PMID 18412750.
- Sellman D (2009). "The 10 most important things known about addiction". Addiction. 105 (1): 6–13. doi:10.1111/j.1360-0443.2009.02673.x. PMID 19712126.
- "23 Best Psychological Thriller Books That Will Mess with Your Head".
- "Supersensitivity Psychosis: The Evidence". 5 November 2010.
- "Evidence of Neuroleptic Drug-Induced Brain Damage". 20 January 2000.
- Steiner W (1990). "Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder". Acta Psychiatrica Scandinavica. 81 (5): 437–440. doi:10.1111/j.1600-0447.1990.tb05477.x. PMID 1972608. S2CID 36082613.
- Khantzian EJ (1997). "The self-medication hypothesis of substance use disorders: a reconsideration and recent applications". Harv Rev Psychiatry. 4 (5): 231–44. doi:10.3109/10673229709030550. PMID 9385000. S2CID 39531697.
- Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP (October 2002). "Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia". Neuropsychopharmacology. 27 (4): 684–6. doi:10.1016/S0893-133X(02)00325-1. PMID 12377405.
- Silvestri S, Negrete JC, Seeman MV, Shammi CM, Seeman P (April 2004). "Does nicotine affect D2 receptor upregulation? A case-control study". Acta Psychiatr Scand. 109 (4): 313–7, discussion 317–8. doi:10.1111/j.1600-0447.2004.00293.x. PMID 15008806. S2CID 38484071.
- Pristach CA; Smith CM (1996). "Self-reported effects of alcohol use on symptoms of schizophrenia". Psychiatr Serv. 47 (4): 421–3. doi:10.1176/ps.47.4.421. PMID 8689377.
- Anthony, J.C. & Helzer, J.E. 1991, "Syndromes of drug abuse and dependence", in Psychiatric Disorders in America: The Epidemiologic Catchment Area Study, L.N. Robins & D.A. Regier, eds., Free Press, New York, pp. 116–154.
- Berman, S; Noble, EP (1993). "Childhood antecedents of substance misuse". Current Opinion in Psychiatry. 6 (3): 382–7. doi:10.1097/00001504-199306000-00012.
- Banerjee, S., Clancy, C., & Crome, I. 2002, "Co-existing Problems of Mental Disorder and Substance Misuse (dual diagnosis). An Information Manual. Found at http://www.rcpsych.ac.uk", Royal College of Psychiatrists' Research Unit.
- Mueser KT; Drake RE; Wallach MA (1998). "Dual diagnosis: a review of etiological theories". Addictive Behaviors. 23 (6): 717–34. doi:10.1016/S0306-4603(98)00073-2. PMID 9801712.
- Szerman N, Martinez-Raga J, Peris L. et al. Rethinking Dual Disorders. Addictive Disorders & Their Treatment. Epub ahead August 2012
- Zimmerman M, Chelminski I, Young D, et al. (2011). "Does DSM-IV capture the dimensional nature of personality disorders?". J Clin Psychiatry. 72 (10): 1333–1339. doi:10.4088/jcp.11m06974. PMID 21903031.
- Drake, Robert E.; Mercer-McFadden, Carolyn; Mueser, Kim T.; McHugo, Gregory J.; Bond, Gary R. (1998). "Review of Integrated Mental Health and Substance Abuse Treatment for Patients With Dual Disorders". Schizophrenia Bulletin. 24 (4): 589–608. doi:10.1093/oxfordjournals.schbul.a033351. PMID 9853791. Archived from the original on 17 July 2013. Retrieved July 2013. Check date values in:
- Drake, Robert E.; Mueser, Kim T. (2000). "Psychosocial Approaches to Dual Diagnosis". Schizophrenia Bulletin. 26 (1): 105–118. doi:10.1093/oxfordjournals.schbul.a033429. PMID 10755672. Archived from the original on 17 July 2013. Retrieved July 2013. Check date values in:
- Gorman, Christine (3 August 1987). "Bad Trips for the Doubly Troubled". Time. Archived from the original on 23 October 2010. Retrieved July 2013. Check date values in:
- Drake, Robert E.; Essock, Susan M.; Shaner, Andrew; Carey, Kate B.; Minkoff, Kenneth; Kola, Lenore; Lynde, David; Osher, Fred C.; Clark, Robin E.; Rickards, Lawrence (1 April 2001). "Implementing Dual Diagnosis Services for Clients With Severe Mental Illness". Psychiatric Services. 54 (1): 469–476. doi:10.1176/appi.ps.52.4.469. PMID 11274491. Retrieved July 2013. Check date values in:
- Sciacca, K._1991 (1991). "An Integrated Treatment Approach for Severely Mentally Ill Individuals with Substance Disorders". New Directions for Mental Health Services, No. 50, Summer 1991, Chapter 6: Jossey-Bass, Publishers. 1991 (50): 69–84. doi:10.1002/yd.23319915008. PMID 1886551.
- Sciacca, Kathleen (July 1996). "Invited response "On Co-Occurring Addictive and Mental Disorders; A Brief History of the Origins of Dual Diagnosis Treatment and Program Development"". American Journal of Orthopsychiatry. 66 (3). Retrieved July 2013. Check date values in:
- Sciacca, Kathleen; Thompson, Christina M. (Summer 1996). "Program Development and Integrated Treatment Across Systems for Dual Diagnosis: Mental Illness, Drug Addiction And Alcoholism, MIDAA". Journal of Mental Health Administration. 23 (3): 288–297. doi:10.1007/bf02522303. PMID 10172686. S2CID 37817674.
- Blanco, Carlos; Alegría, Analucía A.; Liu, Shang-Min; Secades-Villa, Roberto; Sugaya, Luisa; Davies, Carrie; Nunes, Edward V. (2012). "Differences Among Major Depressive Disorder with and Without Co-occurring Substance Use Disorders and Substance-Induced Depressive Disorder". The Journal of Clinical Psychiatry. 73 (6): 865–873. doi:10.4088/JCP.10m06673. PMID 22480900.
- Sciacca, Kathleen_2009. "Best Practices for Dual Diagnosis Treatment and Program Development: Co-occurring Mental Illness and Substance Disorders in Various Combinations". In Angela Brown-Miller (ed.). The Praeger International Collection on Addictions. 3. Praeger. pp. 161–188.
- Sciacca, K. (2011). "Integrated Group Treatment for People Experiencing Mental Health - Substance Use Problems". In David B. Cooper (ed.). Intervention in Mental Health - Substance Use. Radcliffe Pub. pp. 114–127.
- Sciacca, K.; Hatfield, A. B. (1995). "The Family and the Dually Diagnosed Patient". In Lehman, A. F.; Dixon, L. B. (eds.). Double Jeopardy. Harwood Academic Publishers. pp. 193–209.
- Giglioti, M. A. (October 1986). "Program Initiatives for Dually-Diagnosed at Harlem Valley Psychiatric Center. Dual Diagnosis -Co-occurring Disorders". New York State Commission on Quality of Care Publication (28).
- Samet S, Nunes E, Hassin D, et al. (2006). "Diagnosis of comorbid psychiatric disorders in substance users assesses with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV". American Journal of Psychiatry. 163 (4): 689–696. doi:10.1176/appi.ajp.163.4.689. PMID 16585445.
- Sciacca, K. (1997). "Peer Support for People Challenged by Dual Diagnosis: 'Helpful People in Touch' (Consumer Led Self-Help)" (PDF). In Mowbray, C.T.; Moxley, D.P.; Jasper, C.A.; Howell, L.L. (eds.). Consumers as Providers in Psychosocial Rehabilitation. IAPSRS Publisher. p. 82.
- Adamson, Simon J.; Todd, Fraser C.; Douglas Sellman, J.; Huriwai, Terry; Porter, Joel (2006). "Coexisting Psychiatric Disorders in a New Zealand Outpatient Alcohol and other Drug Clinical Population". Australian & New Zealand Journal of Psychiatry. 40 (2): 164–170. doi:10.1080/j.1440-1614.2006.01764.x. PMID 16476135. S2CID 208628311.